Cantor Fitzgerald initiated coverage of Krystal Biotech with an Overweight rating and $160 price target. The firm is anticipating a very strong Vyjuvek product launch, with over $1B in peak world-wide revenue potential which, along with pipeline optionality, make Krystal Biotech an attractive name to own, the analyst tells investors in a research note. The firm adds it will continue to monitor long-term Vyjuvek per-patient utilization trends since that’s an important unknown to plug into outer year estimates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KRYS:
- Krystal Biotech initiated with a Buy at Citi
- Krystal Biotech Announces FDA Clearance of Investigational New Drug Application for KB408 for the Treatment of Type 1 Alpha-1 Antitrypsin Deficiency
- Krystal Biotech announces FDA clearance of IND application for KB408
- Krystal Biotech CEO sells $6.36M in common stock
- Krystal Biotech to Present at the Morgan Stanley 21st Annual Global Healthcare Conference